Anna FrenchPrincipal at Qiming Venture Partners USA
Anna French, Ph.D. is a Principal at Qiming Venture Partners USA. Dr. French serves on the board of WindMIL Therapeutics and is a board observer with Talaris Therapeutics, Cadent Therapeutics, Let’sGetChecked and Platelet Biogenesis.
Prior to joining Qiming, Dr. French was a management consultant at the Boston Consulting Group (BCG) where she advised leading biopharma companies on their strategy and operations. She also led a global industry-academic consortium focused on cell therapy commercialization. Dr. French earned a D.Phil from the University of Oxford, UK. She has over 20 publications in the field of stem cell research.